Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trialResearch in context

Summary: Background: Microsatellite stable (MSS) and RAS-mutant metastatic colorectal cancer (mCRC) patients are characterized by an immunosuppressive microenvironment and a low response rate to immunotherapy. Chemotherapy and anti-angiogenesis therapy have been reported to potentially promote immu...

Descripción completa

Detalles Bibliográficos

Autores principales:	Xuefeng Fang, Ning Zhu, Chenhan Zhong, Liuhong Wang, Jun Li, Shanshan Weng, Hanguang Hu, Caixia Dong, Dan Li, Yongmao Song, Dong Xu, Jianwei Wang, Lifeng Sun, Jian Wang, Zhanhuai Wang, Hongfeng Cao, Xiujun Liao, Ningjuan Yu, Qian Xiao, Mi Mi, Suzhan Zhang, Kefeng Ding, Ying Yuan
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Elsevier 2023-08-01
Colección:	EClinicalMedicine
Materias:	Microsatellite stable RAS mutation Metastatic colorectal cancer Immune checkpoint inhibitors PD-1
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S2589537023003000
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!